SuperworthProfound Medical EPS PROF
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- $2.71
- Latest quarter, Q2 FY26
- −$0.26
- Fiscal year 2025
- $2.62
- +254% on the year before
Profound Medical's earnings per share was $2.71 over the twelve months to Jun 30, 2026, up 8933% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.26.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.62 | +254% |
| FY2024 | $0.74 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.26 | n/a | $2.71 | |
| Q1 FY26 | $0.19 | −47% | $2.45 | |
| Q4 FY25 | $2.52 | n/a | $2.62 | |
| Q3 FY25 | $0.26 | −32% | −$0.09 | |
| Q2 FY25 | −$0.52 | −286% | $0.03 | |
| Q1 FY25 | $0.36 | +33% | $0.83 | |
| Q4 FY24 | −$0.19 | n/a | $0.74 | |
| Q3 FY24 | $0.38 | n/a | n/a | |
| Q2 FY24 | $0.28 | n/a | n/a | |
| Q1 FY24 | $0.27 | n/a | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest Profound Medical's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PROFProfound Medical | $2.71 | +8933% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| MDXGMimedx | $0.04 | −81% a year |
| MOVMovado | $1.80 | +137% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| NEPHNephros | $0.16 | +33% a year |
| Peer median | $1.27 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Profound Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.